Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Merck & Co
(NY:
MRK
)
131.20
+0.48 (+0.37%)
Official Closing Price
Updated: 7:00 PM EDT, Apr 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Merck & Co
< Previous
1
2
...
5
6
7
8
9
10
11
12
13
...
82
83
Next >
January Effect: 3 Under-the-Radar Stocks Poised for a New Year Jump
December 24, 2023
Are you looking to profit from the January effect? Here are three under-the-radar stocks poised for a new year's jump.
Via
InvestorPlace
MarketBeat Week in Review – 12/18 - 12/22
December 23, 2023
The torrid stock market rally cooled down a little bit heading into the extended holiday weekend; we wish you a Happy Holiday season with friends and family
Via
MarketBeat
Topics
Economy
Exposures
Interest Rates
7 Small-Cap Stocks That Wall Street Loves for Good Reason
December 22, 2023
The market rally is showing signs of broadening to include small-cap stocks, here are seven that analysts are upgrading
Via
InvestorPlace
Patritumab Deruxtecan Granted Priority Review in the U.S. for Certain Patients with Previously Treated Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
December 22, 2023
From
Daiichi Sankyo
Via
Business Wire
7 Best Dow Jones Stocks to Buy for Conservative Investors
December 21, 2023
With many vagaries still surrounding the market, the best Dow Jones stocks for conservative investors offers a safer approach.
Via
InvestorPlace
Topics
Stocks
Exposures
US Equities
Merck's Chronic Cough Treatment Candidate Receives Second Time FDA Rejection
December 21, 2023
The FDA issued a Complete Response Letter (CRL) regarding Merck & Co Inc's (NYSE: MRK) New Drug Application (NDA) for gefapixant under development for the treatment of refractory chronic cough (RCC) or...
Via
Benzinga
Exposures
Product Safety
Merck Provides U.S. Regulatory Update on Gefapixant
December 20, 2023
From
Merck & Co., Inc.
Via
Business Wire
Merck to Participate in the Goldman Sachs Healthcare C-Suite Unscripted Conference
December 20, 2023
From
Merck & Co., Inc.
Via
Business Wire
Better Dividend Stock: Bristol Myers Squibb or Merck?
December 19, 2023
These two pharma stocks have sizable dividend yields. Which is the better buy right now?
Via
The Motley Fool
FDA Grants Priority Review to Merck’s New Biologics License Application for V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed to Protect Adults
December 19, 2023
From
Merck & Co., Inc.
Via
Business Wire
Jim Cramer Slams FTC Chair Lina Khan's Policies For Hampering Investor Returns: 'One-Woman Wrecking Crew For Your Stock Portfolio'
December 18, 2023
He posits that such actions have negatively impacted stock valuations.
Via
Benzinga
C4 Therapeutics blasts off: what's next?
December 18, 2023
As the market soars to new heights, C4 Therapeutics (NASDAQ: CCCC) has become the latest small-cap stock to explode higher in price and volume.
Via
MarketBeat
Topics
ETFs
European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy for New First-Line Indications in Advanced HER2-Negative Gastric or GEJ Adenocarcinoma in Tumors Expressing PD-L1 (CPS ≥1) and Advanced Biliary Tract Cancer
December 18, 2023
From
Merck & Co., Inc.
Via
Business Wire
3 Stocks Down 30% or More This Year That Wall Street Expects to Skyrocket in 2024
December 18, 2023
Analysts think these beaten-down stocks could rebound strongly in the new year.
Via
The Motley Fool
Moderna Just Took a Step Closer to Its Product Launch Goal. Is the Stock a Buy?
December 18, 2023
Moderna's personalized cancer vaccine candidate just delivered excellent clinical trial results.
Via
The Motley Fool
Contaminated Vaccines: FDA Reportedly Finds Cleaning And Expiry Lapses At Moderna's Massachusetts Facility
December 16, 2023
The U.S. Food and Drug Administration (FDA) identified several quality control issues at the primary manufacturing facility of Moderna Inc. (NASDAQ: MRNA)
Via
Benzinga
Exposures
Product Safety
FDA Approves Expanded Indication for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) for the First-Line Treatment of Adult Patients With Locally Advanced or Metastatic Urothelial Cancer
December 15, 2023
From
Merck & Co., Inc.
Via
Business Wire
What's Going On With C4 Therapeutics Stock?
December 15, 2023
C4 Therapeutics, Inc. (NASDAQ: CCCC) shares are trading higher Friday, and the stock has gained more than 350% over the past five days.
Via
Benzinga
FDA Approves Merck's Drug Belzutifan For Type Of Advanced Kidney Cancer In Pretreated Cancer Patients
December 15, 2023
The FDA approved Merck & Co Inc's (NYSE: MRK) Welireg (belzutifan), an oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor, for adult patients with advanced renal cell carcinoma (RCC) following a...
Via
Benzinga
Exposures
Product Safety
FDA Approves Merck’s WELIREG® (belzutifan) for the Treatment of Patients With Advanced Renal Cell Carcinoma (RCC) Following a PD-1 or PD-L1 Inhibitor and a VEGF-TKI
December 14, 2023
From
Merck & Co., Inc.
Via
Business Wire
MRNA Stock Surges as Moderna Teams Up With Merck to Fight Cancer
December 14, 2023
Moderna is in focus after reporting positive results for its cancer treatment today, with MRNA stock surging more than 9%.
Via
InvestorPlace
Moderna CEO Highlights Promising Cancer Vaccine Data: 'Think About The Number Of Lives That Can Be Impacted'
December 14, 2023
Moderna, Inc. (NASDAQ: MRNA) CEO Stéphane Bancel appeared on CNBC's "Squawk Box" Thursday to discuss the company's promising new cancer vaccine developed in
Via
Benzinga
Why Is Moderna (MRNA) Stock Up 11% Today?
December 14, 2023
Moderna stock is on the rise Thursday as investors in MRNA react to positive results from a skin cancer vaccine in a Phase 2b trial.
Via
InvestorPlace
Moderna Stock Is Soaring Today - Here's Why
December 14, 2023
Moderna Inc (NASDAQ: MRNA) and Merck & Co Inc (NYSE: MRK) announced follow-up data from the Phase 2b randomized KEYNOTE-942/mRNA-4157-P201 study of mRNA-4157 (V940), an investigational individualized...
Via
Benzinga
Moderna's Cancer Vaccine Cuts Risk Of Relapse, Death By 49%; Will Shares Jump?
December 14, 2023
Moderna and Merck are already working on a Phase 3 study, but these are long-running tests.
Via
Investor's Business Daily
Moderna And Merck Announce mRNA-4157 (V940) In Combination with Keytruda(R) (Pembrolizumab) Demonstrated Continued Improvement in Recurrence-Free Survival and Distant Metastasis-Free Survival in Patients with High-Risk Stage III/IV Melanoma Following
December 14, 2023
Via
ACCESSWIRE
Pfizer's 2024 Outlook Disappointed Wall Street, But Where Will the Stock Be in 5 Years?
December 14, 2023
Pfizer recently outlined expectations for 2024 results in light of an upcoming $43 billion acquisition of Seagen.
Via
The Motley Fool
Dow Jones Skyrockets To Record Heights, Shatters 37,000 Mark, Fueled By Fed's Dovish Stance
December 13, 2023
The 30 largest blue-chip stocks in the Dow Jones Industrial Average surged to unprecedented highs following the Federal Reserve's decision to keep interest rates steady.
Via
Benzinga
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
What's Going On With Moderna Stock Today?
December 12, 2023
Moderna Inc (NASDAQ: MRNA) announced changes to its operating model to bring focus to its short- and
Via
Benzinga
Why Is C4 Therapeutics (CCCC) Stock Up 72% Today?
December 12, 2023
C4 Therapeutics stock is rising higher on Tuesday as investors in CCCC shares celebrate a new collaboration agreement with Merck.
Via
InvestorPlace
< Previous
1
2
...
5
6
7
8
9
10
11
12
13
...
82
83
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.